[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-mediastinal-b-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-mediastinal-b-cell-lymphoma":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641676","neurocognitive-assessment-in-long-term-survivors-of-lymphoma-100641676",false,"NCT07652476","Neurocognitive Assessment in Long-Term Survivors of Lymphoma","Neurocognitive Assessment in Long-Term Survivors of Lymphoma: An Observational Study by the Fondazione Italiana Linfomi (FIL)","FIL_LymDeCo","Inclusion Criteria:\n\n* Patients with previous diagnosis of classic Hodgkin Lymphoma (cHL) or Diffuse Large B Cell Lymphoma (DLBCL) or Primary Mediastinal B Cell Lymphoma (PMBCL).\n* Patients in complete remission after first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +\u002F- radiotherapy.\n* Age ≥ 25 and ≤ 55 at enrollment.\n* Patients between third and fifth year of follow-up after the end of the first line treatment.\n* Absence of signs or symptoms of disease relapse.\n\nExclusion Criteria:\n\n* Patients with CNS disease localization.\n* Patients that received brain\u002Fneuroaxis radiotherapy.\n* Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.","ALL","25 Years","55 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse.\n\nThe assessment of neurocognitive functioning will be performed through a panel of tests, both self-administered and individually administered (about 1 hour). The administration of these neuropsychological tests should be done according to a standardized and predefined order. If available, according to local practice, a neuropsychologist may be involved in test administration and in the evaluation of the results.\n\nBased on its observational nature, no treatment change or modification or additional exams or visits will be required because of being enrolled in this study.",[26,27,28],"Classic Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)","Primary Mediastinal B Cell Lymphoma","NOT_YET_RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2028-03",{"name":39,"class":40},"Fondazione Italiana Linfomi - ETS","OTHER",7,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100614763","phase-2-amping-up-with-pemjak-100614763","NCT07283822","Amping up With PemJAK","A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed\u002FRefractory T-cell Lymphoma and 9p Amplified Lymphomas","Inclusion Criteria:\n\n* (1) Histologically confirmed relapsed\u002Frefractory HL, PMBCL, GZL, and TCL including the below subtypes:\n\n  * Arm 1: PTCL\n\n    * Nodal PTCL Peripheral T-cell Lymphoma- Not Otherwise Specified (PTCL-NOS)\n    * Anaplastic Large Cell Lymphoma (ALCL) T-follicular Helper Lymphomas (TFH) and its subtypes including angioimmunoblastic T-cell Lymphoma (AITL)\n    * Extranodal NK\u002FT-cell lymphoma\n    * Subcutaneous Panniculitis T-Cell Lymphoma\n  * Arm 2: CTCL\n\n    * Mycosis Fungoides\n    * Sezary Syndrome\n  * Arm 3: exploratory cohort\n\n    * Classic HL\n    * PMBCL\n    * GZL\n* (2) All patients must have received at least one-line systemic therapy.\n\n  * Patients with systemic ALCL must have received prior CD30-directed therapy.\n  * Other PTCL subtypes that express CD30 (\\>10%), must have received prior CD30-directed therapy.\n  * Special Consideration for CTCL in Arm 2:\n\n    * Systemic therapies including bexarotene (targretin) are permissible up to 2 weeks prior to enrollment.\n    * Skin directed therapies including light therapy\u002Fphototherapy, extracorporeal photopheresis (ECP), topical steroids, or mechlorethamine (valchlor) gel are NOT considered a systemic line of therapy when given alone.\n    * Treatment with radiation, phototherapy, histone deacetylase inhibitor, retinoids, interferons, therapeutic doses of systemic corticosteroids, or denileukin diftitox (18 µg\u002Fkg\u002Fday) up to 2 weeks prior to enrollment is allowed.\n    * Treatment with alemutuzumab up to 8 weeks prior to enrollment is permissible.\n* (3) Patients must not have had chemotherapy or immunotherapy within 2 weeks prior to entering the study and must have recovered from adverse events (to grade 1 or less)\n* (4) Anti PD-1\u002FPDL-1is permissible up to two weeks prior to enrollment.\n* (5) Age ≥ 18\n* (6) Participants must have measurable disease, as defined in the protocol\n\n  * Patients must have a PET-CT scan performed within ≤4 weeks.\n  * Contrast enhanced CT scan or MRI of the neck, chest, abdomen, pelvis is permissible, however; PET is preferred.\n* (7) Patients cannot have active central nervous system (CNS) disease. Patients that have been treated and asymptomatic are allowed on study.\n* (8) All participants must be screened for chronic hepatitis B virus (HBV) with hepatitis B viral load and serologies (core antibody, surface antigen, and surface antibody) within 30 days prior to enrollment.\n\n  * Patients with positive Hep B core will need to be on HBV prophylaxis\n  * Patients with positive Hep B core will need to be on HBV prophylaxis.\n* (9) Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. If actively on treatment, HCV viral load mut be undetectable 30 days prior to enrollment.\n* (10) Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test (must be within 26 weeks prior to enrollment).\n* (11) Organ function as assessed by laboratory testing and Eastern Cooperate Oncology Group (ECOG) performance status 0-2 and or a Karnofsky performance score of equal or greater to 50 (see Section 20.1.1, Appendix A) for receipt of ruxolitinib and pembrolizumab.\n\n  * Absolute Neutrophil Count ≥ 1000\u002FμL (not growth factor independent)\n  * Platelets ≥ 70,000\u002FμL (or ≥50,000\u002Fmm3 if known bone marrow involvement with dose modifications allowed. See protocol for specific instructions for dose modifications).\n  * Baseline hemoglobin level ≥ 8 g\u002FdL (irrespective of bone marrow involvement).\n  * Calculated creatinine clearance ≥ 30 ml\u002Fmin using the Cockcroft-Gault formula\n  * Bilirubin ≤ 2 x upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) ≤ 2.5 × ULN\n  * Alanine aminotransferase (ALT) ≤ 2.5 × ULN\n* (12) Ability to understand and the willingness to sign a written informed consent document.\n* (13) Patients with prior history of deep vein thrombosis (DVT) that has been treated or actively requiring anticoagulation are permitted to enroll.\n* (14) Due to the potential teratogenic effects, women of childbearing age must have a documented negative serum β-hCG measured within 2 weeks of starting treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician and Incyte immediately (see protocol). Additionally, both women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence).\n\nContraception should continue for 6 months after you stop taking study drug. Similarly, women must agree to not breastfeed during the entirety of the study period.\n\nExclusion Criteria:\n\n* 1\\) Diagnosis of Adult T-Cell Leukemia\u002FLymphoma (ATLL)\n* 2\\) History of autoimmune disease that requires systemic treatment.\n* 3\\) Has a diagnosis of immunodeficiency or receiving immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* 4\\) Actively chronic systemic steroids therapy (in dosing exceeding 10mg daily of prednisone or its drug equivalent).\n\n  o Patients must be off steroid therapy exceeding 10mg or greater of prednisone (or its equivalent) at the start of therapy.\n* 5\\) Patients with HL and PMBCL patients must not be eligible and agreeable to autologous stem cell transplant.\n\n  o Patients with PMBCL must not be eligible and agreeable to CAR-T.\n* 6\\) Allowed to have disease progression after or refractory to autologous bone marrow transplant.\n* 7\\) Progression after allogeneic stem cell transplantation (SCT) can be determined on a case-by-case basis after discussion with the primary investigator.\n* 8\\) History of solid organ transplant requiring active immunosuppression for which treatment with immunotherapy would be contraindicated.\n* 9\\) Active TB (Tuberculosis Bacillus) at time screening. Prior cases of adequately treated TB are permissible.\n* 10\\) Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients.\n* 11\\) Has severe hypersensitivity (≥ Grade 3) to ruxolitinib and\u002For any of its excipients.\n\nPatients with G1 and G2 hypersensitivity remain eligible.\n\n* 12\\) Inability to swallow or take medications by mouth\n* 13\\) Is pregnant or breastfeeding or expected to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n* 14\\) History of concurrent and active malignancy for which he or she is currently receiving directed therapy for.\n* 15\\) History of major adverse cardiac events such as myocardial infraction or stroke within 6 months of enrollment. Cardiovascular events within 6 months such as pulmonary embolism and deep vein thrombosis is permissible if on therapeutic treatment.\n* 16\\) Subjects with active, systemic, and uncontrolled bacterial, viral, or fungal infections at the time of screening will be excluded from study participation.\n\nExceptions include:\n\nInfections that have been appropriately treated, with evidence of clinical resolution and return to baseline organ function within 14 days prior to study entry.\n\n* Localized, non-systemic infections (e.g., uncomplicated urinary tract infections or cellulitis) that are being actively managed and are not associated with systemic symptoms.\n* Please see section protocol for eligibility requirements specifically for HCV, HBV, HIV and Tuberculosis infections at time of screening.","18 Years","95 Years",{"count":52,"type":22},53,"INTERVENTIONAL",[55],"PHASE2","The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.",[58,59,60,61,62,63,64,28],"Non-Hodgkin Lymphoma","Hodgkin Disease Lymphoma","Non-Hodgkin Lymphoma Refractory\u002F Relapsed","Hodgkin Disease Recurrent","Gray Zone Lymphoma","Peripheral T-cell Lymphoma","Cutaneous T-Cell Lymphomas","RECRUITING","2025-12-06",{"date":68,"type":33},"2025-12-16",{"date":70,"type":33},"2025-12-03",{"date":72,"type":22},"2029-01",{"name":74,"class":40},"Seda S. Tolu",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":53,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":75},"100239288","phase-2-obinutuzumab-and-ice-chemotherapy-in-refractoryrecurrent-cd20-mature-nhl-100239288","NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL","Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL","O-ICE","Inclusion Criteria:\n\n* Patients in first relapse or primary induction failure CD20 positive B-cell leukemia\u002Flymphoma including:\n\n  * Diffuse Large B-Cell Lymphoma\n  * Burkitt Lymphoma\n  * High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)\n  * Primary mediastinal B-cell lymphoma (PMBL)\n  * CD20+ B-lymphoblastic lymphoma\n  * Follicular lymphoma, Grade III\n  * Karnofsky ≥ 60% for patients \\> 16 years of age and\n  * Lansky ≥ 60 for patients ≤ 16 years of age.\n  * Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.\n  * Patients may not have received prior therapy with obinutuzumab (GA101)\n  * Radiation Therapy (XRT): Date of receiving prior XRT must be \\> 2 weeks for local palliative XRT (small port); \\> 6 months must have elapsed if prior craniospinal XRT or if \\> 50% radiation of pelvis; \\> 6 weeks must have elapsed if other substantial bone marrow radiation.\n  * Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.\n  * Adequate organ function.\n\nExclusion Criteria:\n\n* Patients with newly diagnosed, previously untreated B-NHL.\n* Known congenital or acquired immune deficiency.\n* Prior solid organ transplantation.\n* Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.\n* History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies\n* Uncontrolled hepatitis B and\u002For C infection","3 Years","31 Years",{"count":87,"type":22},25,[55],"The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).",[58,91,92,93,94,95],"Burkitt Lymphoma","Diffuse Large B-Cell Lymphoma","Primary Mediastinal B-cell Lymphoma","CD20+ Lymphoblastic Lymphoma","Follicular Lymphoma, Grade III","2025-08-07",{"date":98,"type":33},"2025-08-08",{"date":100,"type":33},"2015-08-21",{"date":102,"type":22},"2027-12",{"name":104,"class":40},"New York Medical College",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100576142","study-in-patients-with-relapsedrefractory-primary-mediastinal-lymphoma-treated-with-pembrolizumab-or-nivolumab-in-combination-with-brentuximab-vedotin-in-a-real-life-context-100576142","NCT06781450","Study in Patients With Relapsed\u002FRefractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","Retrospective Observational Study in Patients With Relapsed \u002F Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context","PRIMICI","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021\n2. Age ≥ 18 years at enrollment\n3. Signature of written informed consent (where applicable)\n\nExclusion Criteria:\n\n1\\. Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.",{"count":114,"type":22},50,"Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed\u002FRefractory",[28],[118,119,120],"pembrolizumab","nivolumab","brentuximab vedotin","2025-01-28",{"date":123,"type":33},"2025-01-30",{"date":125,"type":33},"2022-04-23",{"date":127,"type":22},"2025-12",{"name":129,"class":40},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3,"Primary Mediastinal B-Cell Lymphoma"]